Aduhelm (aducanumab), approved for Alzheimer’s disease in the U.S., is most appropriate for people with mild cognitive impairment (MCI) due to the disease or early Alzheimer’s dementia, the disorders for which it was tested in clinical trials and subsequently approved, according to experts from the scientific community. The experts discussed the path forward for Aduhelm following its U.S. approval at a meeting convened by the Alzheimer’s Association, which published a press release with details from…
You must be logged in to read/download the full post.
The post Aduhelm Most Appropriate for Early-stage Alzheimer’s, Experts Say appeared first on BioNewsFeeds.